Latest Information
Wednesday, June 16, 2010
Health Canada has approved Votrient (pazopanib) for metastatic renal cell carcinoma.
Friday, June 4, 2010
Effective June 14, 2010 Torisel will be funded in Ontario under the Ministry of Health
Wednesday, May 26, 2010
A Canadian retrospective single-centre review of advanced RCC patients reports that macrocytosis occurred in 21 of 43 patients (48.8%) during sunitinib treatment.
Print this page Tell A Friend Add to Favorites

Votrient (pazopanib) Approved by Health Canada for the Treatment of Renal Cell Carcinoma

Thursday, July 08, 2010 - admin
Wednesday, June 16, 2010
Original Article

Health Canada has approved Votrient (pazopanib) for metastatic renal cell carcinoma. According to the Health Canada announcement, the Notice of Compliance (NOC) states that pazopanib has been approved for first-line treatment of metastatic clear cell renal cell carcinoma, or second-line treatment following cytokine therapy (such as Inteferon or Interleukin).

Submissions will be made to the Joint Oncology Drug Review (JODR) and to the Conseil de medicament (Quebec) for reimbursement recommendations. Based upon past experiences, it is understood that this process, including provincial decisions on funding, may take up to one year after the submission is made to Joint Oncology Drug Review. Further information about programs for accessing pazopanib will be available on www.kidneycancercanada.org when known. In the meantime, patients with private drug insurance may be able to access pazopanib beginning later this summer when supplies are available in Canada.

If you have any questions about Votrient/pazopanib for mrcc, please ask your oncologist.
Filed Under: Uncategorized